Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 18 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

The right idea for the wrong patient: results of a national survey on stopping PPIs

The Right Idea for the Wrong Patient: Results of a National Survey on Stopping PPIs

News image

Recent studies have linked proton pump inhibitor use to serious adverse effects, including bone fracture, chronic kidney disease, dementia, and ischemic stroke.

Although it remains unclear whether proton pump inhibitors truly cause these adverse effects, this potential has forced physicians to carefully consider the safety 
and utility of long-term PPI use in their patients, a topic included in the American Board of Internal Medicine Foundation’s Choosing Wisely campaign.

Using case vignettes, Dr Jacob Kurlander and colleagues from Michigan, USA evaluated internists’ willingness to stop proton pump inhibitor varies according to drug indication.

In 2013, the reseachers conducted an online, cross-sectional survey of a representative sample of the American College of Physicians using their Internal Medicine Insider Research Panel.
Respondents shown the high-risk vignette were 1.93 times more likely to stop proton pump inhibitor
Clinical Gastroenterology & Hepatology

Physicians spending 25% of their time in direct patient care were invited.

The research team developed 3 patient vignettes, all featuring a 70-year-old woman prescribed omeprazole, 20 mg daily, and recently diagnosed with osteopenia,  increasing her risk of bone fracture, a reported PPI adverse effect.

The vignettes differed in proton pump inhibitor indication:  gastroesophageal reflux disease  well controlled for years with normal upper endoscopy;  prevention of 
upper gastrointestinal bleeding  while on low-dose aspirin  and warfarin, otherwise asymptomatic; or  prevention of upper gastrointestinal bleeding while on low-dose 
aspirin alone with a history of nonsteroidal anti-inflammatory drug–related peptic ulcer disease 10 years prior, otherwise asymptomatic.

The 3 vignettes represented low-, moderate-, and high-risk for upper gastrointestinal bleeding, respectively, and bleeding risk was not explicitly stated in the vignettes.

Respondents were presented at random with 2 of the 3 patient vignettes to minimize respondent fatigue.

For each vignette, the researchers asked respondents how likely they would be to stop proton pump inhibitor on a 1–7 Likert-type scale.

The researchers also asked participants how concerned they were about long-term pump inhibitor indication adverse effects on a 1–7 Likert-type scale.

The reserchers hypothesized that physicians would be most likely to recommend proton pump inhibitor stopping in the patient with gastroesophageal reflux disease.

A total of 487 of 914 invited participants completed the survey. 

The team found that the median age was in the 5th decade of life, and 30% were female.

The researchers noted that a total of 22% were trainees, 58% practiced general medicine, 2% gastroenterology, and 18% another subspecialty.

The team observed that on a 1–7 scale, most physicians reported moderate concern about PPI adverse effects.

For the patient vignette with high risk for upper gastrointestinal bleeding , 62% of respondents would stop the proton pump inhibitor, compared with 47% for the 
moderate-risk vignette, and only 32% for the low-risk vignette.

The team noted that respondents shown the moderate-risk vignette were 1.47 times  more likely to stop proton pump inhibitor relative to the low-risk vignette, whereas respondents shown the high-risk vignette were 1.93 times more likely to stop proton pump inhibitor relative to the low-risk.

Dr Kurlander's team concludes,  "For every 1-point increase on the 7-point scale of concern about proton pump inhibitor adverse effects, probability of stopping proton pump inhibitor increased by 11%."

"Older physician age  and being a current trainee  were both independently associated with a lower probability of stopping." 

Clin Gastroenterol Hepatol 2017: 15: 1475–1476
14 September 2017

Go to top of page Email this page Email this page to a colleague

 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Socioeconomic characteristics in diverticular disease
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Barriers to hepatitis C treatment
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 31 October 2017 
Endoscopic indices of disease activity for Crohn’s
 31 October 2017 
Follow-up of positive results on fecal blood tests
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us